Cite

    B. Glintborg et al.. “FRI0103 One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study.” Annals of the rheumatic diseases, vol. 77, n.d., pp. 595–596. http://access.bl.uk/ark:/81055/vdc_100144719046.0x00004d